Sign In
Last checked at 
15 Oct 2025 07:00
IXICO plc
("IXICO", the "Company" or the "Group")
New blood based biomarker contract win and
contract extension worth a total of £1.2 million.
15 October 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced that it has signed a new commercial contract to assist in the validation of a diagnostic blood test, reaffirming the Company's expertise in this area. IXICO has also entered into a contract extension on an existing Alzheimer's Disease (AD) clinical trial. The combined value of the new contract and contract extension is c. £1.2 million.
The new contract, with a leading global biopharma company, will run over a contract period of under three years and will use IXICO's platform to facilitate the analysis of a prospective blood-based biomarker test to aid the diagnosis of a non-disclosed neurodegenerative disease. The contract extension adds a range of activities to an existing AD clinical trial being supported by IXICO over the next few years. This significant extension reflects a series of smaller scope additions with existing biopharma clients over the last couple of months and provides additional strength to IXICO's long term order book.
The positive commercial momentum continues IXICO's successful execution of its 'Innovate, Lead, Scale' strategy to drive global expansion and growth.
Bram Goorden, CEO of IXICO, commented: "The new contract win marks our continued expansion and expertise in the blood-based biomarker field. The sustained period of contract extensions culminating in this important AD clinical trial, demonstrates the demand for IXICO's services and expertise, the consistent quality of our work, and the value we provide to major biopharma clients."
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Ends
For further information please contact:
IXICO plc | +44 (0) 20 3763 7499 |
Grant Nash, Chief Financial Officer James Chandler, Chief Business Officer | |
Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker) |
+44 (0) 20 7220 0500 |
Giles Balleny (Corporate Finance) Nigel Birks (Healthcare Specialist Sales) Harriet Ward (Corporate Broking) Michael F Johnson (Sales) |
About IXICO www.IXICO.com
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech's, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.
The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer's, Huntington's and Parkinson's. Image data is interrogated by the Platform and IXICO's expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.
Follow the stocks
